BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ungaro RC, Brenner EJ, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, Ng SC, Rahier JF, Reinisch W, Steinwurz F, Underwood FE, Zhang X, Colombel JF, Kappelman MD. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut 2021;70:725-32. [PMID: 33082265 DOI: 10.1136/gutjnl-2020-322539] [Cited by in Crossref: 59] [Cited by in F6Publishing: 76] [Article Influence: 29.5] [Reference Citation Analysis]
Number Citing Articles
1 Anjum MR, Chalmers J, Hamid R, Rajoriya N. COVID-19: Effect on gastroenterology and hepatology service provision and training: Lessons learnt and planning for the future. World J Gastroenterol 2021; 27(44): 7625-7648 [PMID: 34908803 DOI: 10.3748/wjg.v27.i44.7625] [Reference Citation Analysis]
2 Neurath MF. COVID-19: biologic and immunosuppressive therapy in gastroenterology and hepatology. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34188251 DOI: 10.1038/s41575-021-00480-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Lees CW, Irving PM, Beaugerie L. COVID-19 and IBD drugs: should we change anything at the moment? Gut 2021;70:632-4. [PMID: 33214164 DOI: 10.1136/gutjnl-2020-323247] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Kennedy NA, Goodhand JR, Bewshea C, Nice R, Chee D, Lin S, Chanchlani N, Butterworth J, Cooney R, Croft NM, Hart AL, Irving PM, Kok KB, Lamb CA, Limdi JK, Macdonald J, McGovern DP, Mehta SJ, Murray CD, Patel KV, Pollok RC, Raine T, Russell RK, Selinger CP, Smith PJ, Bowden J, McDonald TJ, Lees CW, Sebastian S, Powell N, Ahmad T; Contributors to the CLARITY IBD study. Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab.Gut. 2021;70:865-875. [PMID: 33753421 DOI: 10.1136/gutjnl-2021-324388] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 27.0] [Reference Citation Analysis]
5 Bernstein CN, Singh H, Murthy SK, Nguyen GC, Benchimol EI, Bitton A, Kuenzig ME, Huang JG, Jones JL, Lee K, Targownik LE, Windsor JW, Mukhtar MS, Tandon P, Kaplan GG. Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Seniors With IBD. J Can Assoc Gastroenterol 2021;4:S34-9. [PMID: 34755037 DOI: 10.1093/jcag/gwab025] [Reference Citation Analysis]
6 Chebli JMF, Queiroz NSF, Damião AOMC, Chebli LA, Costa MHM, Parra RS. How to manage inflammatory bowel disease during the COVID-19 pandemic: A guide for the practicing clinician. World J Gastroenterol 2021; 27(11): 1022-1042 [PMID: 33776370 DOI: 10.3748/wjg.v27.i11.1022] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
7 Pinto S, Loddo E, Paba S, Favale A, Chicco F, Onali S, Usai P, Fantini MC. Crohn's disease and ulcerative colitis patient-reported outcomes signs and symptoms for the remote management of inflammatory bowel disease during the COVID-19 pandemic. J Patient Rep Outcomes 2021;5:48. [PMID: 34165646 DOI: 10.1186/s41687-021-00323-z] [Reference Citation Analysis]
8 Lee YJ, Kim SE, Park YE, Chang JY, Song HJ, Kim DH, Yang YJ, Kim BC, Lee JG, Yang HC, Choi M, Myung SJ; Clinical Practice Guideline Committee of the Korean Association for the Study of the Intestinal Diseases. [SARS-CoV-2 Vaccination for Adult Patients with Inflammatory Bowel Disease: Expert Consensus Statements by KASID]. Korean J Gastroenterol 2021;78:117-28. [PMID: 34446634 DOI: 10.4166/kjg.2021.110] [Reference Citation Analysis]
9 Bekic D, Belosic Halle Z. Inflammatory bowel disease and SARS-CoV-2 pandemic: current knowledge and recommendations. Scand J Gastroenterol 2021;56:656-60. [PMID: 33765405 DOI: 10.1080/00365521.2021.1902561] [Reference Citation Analysis]
10 Queiroz NSF, Teixeira FV, Motta MP, Chebli LA, Hino AAF, Martins CA, Quaresma AB, Silva AAPD, Damião AOMC, Saad-Hossne R, Kotze PG. Risk stratification and geographical mapping of Brazilian inflammatory bowel disease patients during the COVID-19 outbreak: Results from a nationwide survey. World J Gastroenterol 2021; 27(12): 1226-1239 [PMID: 33828396 DOI: 10.3748/wjg.v27.i12.1226] [Reference Citation Analysis]
11 Nørgård BM, Zegers FD, Nielsen J, Kjeldsen J. Post COVID-19 hospitalizations in patients with chronic inflammatory diseases - A nationwide cohort study. J Autoimmun 2021;125:102739. [PMID: 34757259 DOI: 10.1016/j.jaut.2021.102739] [Reference Citation Analysis]
12 Zhou B, Li S, Ye J, Liu Y, Hu L, Tang Y, Wu Z, Zhang P. Immunopathological events surrounding IL-6 and IFN-α: A bridge for anti-lupus erythematosus drugs used to treat COVID-19. Int Immunopharmacol 2021;101:108254. [PMID: 34710657 DOI: 10.1016/j.intimp.2021.108254] [Reference Citation Analysis]
13 Winchester N, Calabrese C, Calabrese LH. The Intersection of COVID-19 and Autoimmunity: What is Our Current Understanding? Pathog Immun 2021;6:31-54. [PMID: 33969248 DOI: 10.20411/pai.v6i1.417] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
14 Puoti MG, Rybak A, Kiparissi F, Gaynor E, Borrelli O. SARS-CoV-2 and the Gastrointestinal Tract in Children. Front Pediatr 2021;9:617980. [PMID: 33692973 DOI: 10.3389/fped.2021.617980] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
15 Gelfand JM, Armstrong AW, Bell S, Anesi GL, Blauvelt A, Calabrese C, Dommasch ED, Feldman SR, Gladman D, Kircik L, Lebwohl M, Lo Re V 3rd, Martin G, Merola JF, Scher JU, Schwartzman S, Treat JR, Van Voorhees AS, Ellebrecht CT, Fenner J, Ocon A, Syed MN, Weinstein EJ, Gondo G, Heydon S, Koons S, Ritchlin CT. National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. J Am Acad Dermatol 2021;84:1254-68. [PMID: 33422626 DOI: 10.1016/j.jaad.2020.12.058] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 16.0] [Reference Citation Analysis]
16 Madhu D, Sharma S, Agarwal A, Saraya A. Special Considerations in the Management of Autoimmune Hepatitis in COVID-19 Hotspots: A Review. J Clin Transl Hepatol 2021;9:568-75. [PMID: 34447687 DOI: 10.14218/JCTH.2021.00001] [Reference Citation Analysis]
17 Tripathi K, Godoy Brewer G, Thu Nguyen M, Singh Y, Saleh Ismail M, Sauk JS, Parian AM, Limketkai BN. COVID-19 and Outcomes in Patients With Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. Inflamm Bowel Dis 2021:izab236. [PMID: 34718595 DOI: 10.1093/ibd/izab236] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Ungaro RC, Colombel JF, Dubinsky MC, Jain A, Dervieux T. Impact of Thiopurine Exposure on Immunogenicity to Infliximab Is Negligible in the Setting of Elevated Infliximab Concentrations. Inflamm Bowel Dis 2021:izab232. [PMID: 34536078 DOI: 10.1093/ibd/izab232] [Reference Citation Analysis]
19 Ungaro RC, Kappelman MD, Rubin DT, Colombel JF. COVID-19 and Inflammatory Bowel Disease: Lessons Learned, Practical Recommendations, and Unanswered Questions.Gastroenterology. 2021;160:1447-1451. [PMID: 33387525 DOI: 10.1053/j.gastro.2020.12.042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Kaplan GG, Underwood FE, Coward S, Agrawal M, Ungaro RC, Brenner EJ, Gearry RB, Kissous-Hunt M, Lewis JD, Ng SC, Rahier JF, Reinisch W, Steinwurz F, Zhang X, Kappelman MD, Colombel JF. The Multiple Waves of COVID-19 in Patients With Inflammatory Bowel Disease: A Temporal Trend Analysis. Inflamm Bowel Dis 2022:izab339. [PMID: 35032167 DOI: 10.1093/ibd/izab339] [Reference Citation Analysis]
21 Assa A, Benninga MA, Borrelli O, Broekaert I, de Carpi JM, Saccomani MD, Dolinsek J, Mas E, Miele E, Thomson M, Tzivinikos C; Gastrointestinal Committee of ESPGHAN. Gastrointestinal Perspective of Coronavirus Disease 2019 in Children-An Updated Review. J Pediatr Gastroenterol Nutr 2021;73:299-305. [PMID: 34117195 DOI: 10.1097/MPG.0000000000003204] [Reference Citation Analysis]
22 Bourgonje AR, van Linschoten RCA, West RL, van Dijk MA, van Leer-Buter CC, Kats-Ugurlu G, Pierik MJ, Festen EAM, Weersma RK, Dijkstra G. Treatment of severe acute ulcerative colitis in SARS-CoV-2 infected patients: report of three cases and discussion of treatment options. Therap Adv Gastroenterol 2021;14:17562848211012595. [PMID: 33995584 DOI: 10.1177/17562848211012595] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Regierer AC, Hasseli R, Schäfer M, Hoyer BF, Krause A, Lorenz HM, Pfeil A, Richter J, Schmeiser T, Schulze-Koops H, Strangfeld A, Voll RE, Specker C, Mueller-Ladner U. TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD. RMD Open 2021;7:e001896. [PMID: 34670840 DOI: 10.1136/rmdopen-2021-001896] [Reference Citation Analysis]
24 Dvornikova KA, Bystrova EY, Churilov LP, Lerner A. Pathogenesis of the inflammatory bowel disease in context of SARS-COV-2 infection. Mol Biol Rep 2021;48:5745-58. [PMID: 34296352 DOI: 10.1007/s11033-021-06565-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Revés JB, Frias-Gomes C, Morão B, Nascimento C, Palmela C, Fidalgo C, Roque Ramos L, Sampaio A, Glória L, Cravo M, Torres J. Inflammatory Bowel Disease Patients' Perspectives during COVID-19 Pandemic: Results from a Portuguese Survey. GE Port J Gastroenterol 2021;5:1-9. [PMID: 34934777 DOI: 10.1159/000518945] [Reference Citation Analysis]
26 Ferretti F, Cannatelli R, Benucci M, Carmagnola S, Clementi E, Danelli P, Dilillo D, Fiorina P, Galli M, Gallieni M, Genovese G, Giorgi V, Invernizzi A, Maconi G, Maier JA, Marzano AV, Morpurgo PS, Nebuloni M, Radovanovic D, Riva A, Rizzardini G, Sabiu G, Santus P, Staurenghi G, Zuccotti G, Sarzi-Puttini PC, Ardizzone S. How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group. Front Immunol 2021;12:656362. [PMID: 33936084 DOI: 10.3389/fimmu.2021.656362] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
27 Fagni F, Simon D, Tascilar K, Schoenau V, Sticherling M, Neurath MF, Schett G. COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses. Lancet Rheumatol 2021;3:e724-36. [PMID: 34485930 DOI: 10.1016/S2665-9913(21)00247-2] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
28 Ahmed W, Taft TH, Charabaty A. Social media in inflammatory bowel disease: the patient and physician perspective. Curr Opin Gastroenterol 2021;37:328-35. [PMID: 33859103 DOI: 10.1097/MOG.0000000000000742] [Reference Citation Analysis]
29 Ellen Kuenzig M, Windsor JW, Barrett L, Bernstein CN, Bitton A, Carroll MW, Chauhan U, Coward S, Fowler S, Ghia JE, Geist R, Gibson DL, Graff LA, Griffiths AM, Guoxian Huang J, Jones JL, Khanna R, Lakatos PL, Lee K, Mack DR, Marshall JK, Mukhtar MS, Murthy SK, Nguyen GC, Panaccione R, Seow CH, Singh H, Tandon P, Targownik LE, Zelinsky S, Benchimol EI, Kaplan GG. Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Executive Summary. J Can Assoc Gastroenterol 2021;4:S1-9. [PMID: 34755033 DOI: 10.1093/jcag/gwab027] [Reference Citation Analysis]
30 Cao TT, Zhang GQ, Pellegrini E, Zhao Q, Li J, Luo LJ, Pan HQ. COVID-19 and its effects on the digestive system. World J Gastroenterol 2021; 27(24): 3502-3515 [PMID: 34239265 DOI: 10.3748/wjg.v27.i24.3502] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
31 Ungaro RC, Brenner EJ, Agrawal M, Zhang X, Kappelman MD, Colombel JF; Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) Research Group. Impact of Medications on COVID-19 Outcomes in Inflammatory Bowel Disease: Analysis of More Than 6000 Patients From an International Registry. Gastroenterology 2021:S0016-5085(21)03490-9. [PMID: 34529987 DOI: 10.1053/j.gastro.2021.09.011] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Ricciuto A, Lamb CA, Benchimol EI, Walker GJ, Kennedy NA, Kuenzig ME, Kaplan GG, Kappelman MD, Ungaro RC, Colombel JF, Brenner EJ, Agrawal M, Reinisch W, Griffiths AM, Sebastian S. Inflammatory Bowel Disease Clinical Activity Is Associated with COVID-19 Severity Especially in Younger Patients. J Crohns Colitis 2021:jjab172. [PMID: 34570886 DOI: 10.1093/ecco-jcc/jjab172] [Reference Citation Analysis]
33 Schulz C, Mayerle J, Lerch MM, Malfertheiner P. [Update 2021: COVID-19 from the perspective of gastroenterology]. Dtsch Med Wochenschr 2021;146:891-3. [PMID: 34256402 DOI: 10.1055/a-1449-4054] [Reference Citation Analysis]
34 Park YE, Lee YJ, Chang JY, Song HJ, Kim DH, Yang YJ, Kim BC, Lee JG, Yang HC, Choi M, Kim SE, Myung SJ; Clinical Practice Guideline Committee of the Korean Association for the Study of the Intestinal Diseases. [KASID Guidance for Clinical Practice Management of Adult Inflammatory Bowel Disease during the COVID-19 Pandemic: Expert Consensus Statement]. Korean J Gastroenterol 2021;78:105-16. [PMID: 34446633 DOI: 10.4166/kjg.2021.112] [Reference Citation Analysis]
35 Sperger J, Shah KS, Lu M, Zhang X, Ungaro RC, Brenner EJ, Agrawal M, Colombel JF, Kappelman MD, Kosorok MR. Development and validation of multivariable prediction models for adverse COVID-19 outcomes in IBD patients. medRxiv 2021:2021. [PMID: 33501455 DOI: 10.1101/2021.01.15.21249889] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Agrawal M, Zhang X, Brenner EJ, Ungaro RC, Kappelman MD, Colombel JF. The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry. J Crohns Colitis 2021;15:1877-84. [PMID: 33884425 DOI: 10.1093/ecco-jcc/jjab071] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
37 Schreiber S, Ben-Horin S, Alten R, Westhovens R, Peyrin-Biroulet L, Danese S, Hibi T, Takeuchi K, Magro F, An Y, Kim DH, Yoon S, Reinisch W. Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era. Adv Ther 2022. [PMID: 34988877 DOI: 10.1007/s12325-021-01990-6] [Reference Citation Analysis]
38 Alvarado DM, Son J, Thackray LB, Gomez Castro MF, Prasad S, Cui X, Sonnek NM, Diamond MS, Ding S, Ciorba MA. Mesalamine Reduces Intestinal ACE2 Expression Without Modifying SARS-CoV-2 Infection or Disease Severity in Mice. Inflamm Bowel Dis 2021:izab274. [PMID: 34849936 DOI: 10.1093/ibd/izab274] [Reference Citation Analysis]
39 Sebastian S, Walker GJ, Kennedy NA, Conley TE, Patel KV, Subramanian S, Kent AJ, Segal JP, Brookes MJ, Bhala N, Gonzalez HA, Hicks LC, Mehta SJ, Lamb CA;  PROTECT-ASUC Study Group. Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study. Lancet Gastroenterol Hepatol. 2021;6:271-281. [PMID: 33545083 DOI: 10.1016/s2468-1253(21)00016-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
40 [DOI: 10.1101/2021.03.17.21253848] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Horst S. Covid-19 and Patients with IBD: Who Is at Highest Risk for Severe Complications? Dig Dis Sci 2021. [PMID: 34181167 DOI: 10.1007/s10620-021-07106-y] [Reference Citation Analysis]
42 Targownik LE, Bernstein CN, Lakatos PL, Murthy SK, Benchimol EI, Bitton A, Huang JG, Kuenzig ME, Jones JL, Kaplan GG, Lee K, Mukhtar MS, Tandon P, Windsor JW, Panaccione R. Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Risk Factors and Medications. J Can Assoc Gastroenterol 2021;4:S40-5. [PMID: 34755038 DOI: 10.1093/jcag/gwab032] [Reference Citation Analysis]
43 Efe C, Lammert C, Taşçılar K, Dhanasekaran R, Ebik B, Higuera-de la Tijera F, Calışkan AR, Peralta M, Gerussi A, Massoumi H, Catana AM, Purnak T, Rigamonti C, Aldana AJG, Khakoo N, Nazal L, Frager S, Demir N, Irak K, Melekoğlu-Ellik Z, Kacmaz H, Balaban Y, Atay K, Eren F, Alvares-da-Silva MR, Cristoferi L, Urzua Á, Eşkazan T, Magro B, Snijders R, Barutçu S, Lytvyak E, Zazueta GM, Demirezer-Bolat A, Aydın M, Heurgue-Berlot A, De Martin E, Ekin N, Yıldırım S, Yavuz A, Bıyık M, Narro GC, Kıyıcı M, Akyıldız M, Kahramanoğlu-Aksoy E, Vincent M, Carr RM, Günşar F, Reyes EC, Harputluoğlu M, Aloman C, Gatselis NK, Üstündağ Y, Brahm J, Vargas NCE, Güzelbulut F, Garcia SR, Aguirre J, Anders M, Ratusnu N, Hatemi I, Mendizabal M, Floreani A, Fagiuoli S, Silva M, Idilman R, Satapathy SK, Silveira M, Drenth JPH, Dalekos GN, N Assis D, Björnsson E, Boyer JL, Yoshida EM, Invernizzi P, Levy C, Montano-Loza AJ, Schiano TD, Ridruejo E, Wahlin S. Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis. Liver Int 2021. [PMID: 34846800 DOI: 10.1111/liv.15121] [Reference Citation Analysis]
44 Eder P, Łodyga M, Dobrowolska A, Reguła J, Rydzewska G. Position statement of the Polish Society of Gastroenterology and the National Gastroenterology Consultant on vaccination against COVID-19 among patients with inflammatory bowel diseases. Prz Gastroenterol 2021;16:2-4. [PMID: 33986880 DOI: 10.5114/pg.2021.103666] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Crouwel F, Waaijenberg-Warmenhoven P, Buiter HJC, de Boer NK. Recurrent COVID-19 in a Patient With Ulcerative Colitis on Vedolizumab Therapy. J Crohns Colitis 2021;15:1244-5. [PMID: 33350449 DOI: 10.1093/ecco-jcc/jjaa259] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Dipasquale V, Passanisi S, Cucinotta U, Cascio A, Romano C. Implications of SARS-COV-2 infection in the diagnosis and management of the pediatric gastrointestinal disease. Ital J Pediatr 2021;47:71. [PMID: 33761992 DOI: 10.1186/s13052-021-01020-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Ruan W, Nguyen H, Wyatt A, Ihekweazu F, Vartabedian BS, Karam L, Walsh S, Kellermayer R. High Seroconversion Rate Against Severe Acute Respiratory Syndrome Coronavirus 2 in Symptomatic Pediatric Inflammatory Bowel Disease Patients. J Pediatr Gastroenterol Nutr 2021;73:363-6. [PMID: 34173793 DOI: 10.1097/MPG.0000000000003211] [Reference Citation Analysis]
48 Wu X, Lin J, Buch H, Ding Q, Zhang F, Cui B, Ji G. The COVID-19 Vaccination Hesitancy Among the People With Inflammatory Bowel Disease in China: A Questionnaire Study. Front Public Health 2021;9:731578. [PMID: 34708016 DOI: 10.3389/fpubh.2021.731578] [Reference Citation Analysis]
49 Wong SY, Dixon R, Martinez Pazos V, Gnjatic S, Colombel JF, Cadwell K; ICARUS-IBD Working Group. Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies. Gastroenterology 2021;161:715-718.e4. [PMID: 33887219 DOI: 10.1053/j.gastro.2021.04.025] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 11.0] [Reference Citation Analysis]
50 Murthy SK, Kuenzig ME, Windsor JW, Ghia JE, Griffiths AM, Panaccione R, Seow CH, Benchimol EI, Bernstein CN, Bitton A, Huang JG, Jones JL, Lee K, Kaplan GG, Mukhtar MS, Tandon P, Targownik LE, Gibson DL. Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: COVID-19 Vaccines-Biology, Current Evidence and Recommendations. J Can Assoc Gastroenterol 2021;4:S54-60. [PMID: 34755040 DOI: 10.1093/jcag/gwab033] [Reference Citation Analysis]
51 Khan N, Patel D, Trivedi C, Pernes T, Kavani H, Xie D, Yang YX. The impact of IBD medications on risk of pneumonia and pneumonia-related hospitalisation: a nationwide cohort study of 56 410 IBD patients. Aliment Pharmacol Ther 2022;55:64-72. [PMID: 34664313 DOI: 10.1111/apt.16610] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
52 Jefremow A, Neurath MF. SARS-CoV-2 Virus Manifestations in the Gastrointestinal Tract: Therapeutic Implications. Visc Med 2021;37:63-9. [PMID: 33693046 DOI: 10.1159/000513180] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
53 Chen F, Dai Z, Huang C, Chen H, Wang X, Li X. Gastrointestinal Disease and COVID-19: A Review of Current Evidence. Dig Dis 2021. [PMID: 34510032 DOI: 10.1159/000519412] [Reference Citation Analysis]
54 Wetwittayakhlang P, Albader F, Golovics PA, Hahn GD, Bessissow T, Bitton A, Afif W, Wild G, Lakatos PL. Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease. Can J Gastroenterol Hepatol 2021;2021:7591141. [PMID: 34858891 DOI: 10.1155/2021/7591141] [Reference Citation Analysis]
55 Gilissen LPL, Heinen SGH, Rijpma-Jacobs L, Schoon E, Schreuder RM, Wensing AM, van der Ende-van Loon MCM, Bloemen JG, Stapelbroek JM, Stronkhorst A. Neither inflammatory bowel disease nor immunosuppressants are associated with an increased risk of severe COVID-19: an observational Dutch cohort study. Clin Exp Med 2021. [PMID: 34542781 DOI: 10.1007/s10238-021-00755-3] [Reference Citation Analysis]
56 Prentice RE, Rentsch C, Al-Ani AH, Zhang E, Johnson D, Halliday J, Bryant R, Begun J, Ward MG, Lewindon PJ, Connor SJ, Ghaly S, Christensen B. SARS-CoV-2 vaccination in patients with inflammatory bowel disease. GastroHep 2021;3:212-28. [PMID: 34539248 DOI: 10.1002/ygh2.473] [Reference Citation Analysis]
57 Greco R, Alexander T, Burman J, Del Papa N, de Vries-Bouwstra J, Farge D, Henes J, Kazmi M, Kirgizov K, Muraro PA, Ricart E, Rovira M, Saccardi R, Sharrack B, Snarski E, Withers B, Jessop H, Boglione C, Kramer E, Badoglio M, Labopin M, Orchard K, Corbacioglu S, Ljungman P, Mikulska M, De la Camara R, Snowden JA; European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP), Infectious Diseases Working Party (IDWP), Pediatric Working Party (PWP), Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT) and EBMT (JACIE), EBMT Nurses Group and Patient Advocacy Committee. Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations. Bone Marrow Transplant 2021;56:1493-508. [PMID: 34031556 DOI: 10.1038/s41409-021-01326-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
58 Nowak JK, Kalla R, Satsangi J. Reply. Gastroenterology 2021;160:2622-3. [PMID: 33549534 DOI: 10.1053/j.gastro.2021.02.011] [Reference Citation Analysis]
59 Sparks JA, Wallace ZS, Robinson PC. Coronavirus disease 2019: update on coronavirus disease 2019 outcomes and vaccine efficacy in patients with immune-mediated inflammatory disease. Curr Opin Rheumatol 2021;33:412-8. [PMID: 34171857 DOI: 10.1097/BOR.0000000000000812] [Reference Citation Analysis]
60 Meredith J, Henderson P, Wilson DC, Russell RK. Combination Immunotherapy Use and Withdrawal in Pediatric Inflammatory Bowel Disease-A Review of the Evidence. Front Pediatr 2021;9:708310. [PMID: 34621712 DOI: 10.3389/fped.2021.708310] [Reference Citation Analysis]
61 El Ouali S, Rubin DT, Cohen BL, Regueiro MD, Rieder F. Optimal inflammatory bowel disease management during the global coronavirus disease 2019 pandemic. Curr Opin Gastroenterol 2021;37:313-9. [PMID: 33859104 DOI: 10.1097/MOG.0000000000000741] [Reference Citation Analysis]
62 Kjeldsen J, Nielsen J, Ellingsen T, Knudsen T, Nielsen RG, Larsen MD, Lund K, Nørgård BM. Outcome of COVID-19 in hospitalized patients with chronic inflammatory diseases. A population based national register study in Denmark. J Autoimmun 2021;120:102632. [PMID: 33812171 DOI: 10.1016/j.jaut.2021.102632] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
63 Levartovsky A, Ben-Horin S. Anti-TNF Therapy During the SARS-CoV-2 Pandemic: Friend or Foe? J Crohns Colitis 2021:jjab167. [PMID: 34626174 DOI: 10.1093/ecco-jcc/jjab167] [Reference Citation Analysis]
64 Grunert PC, Dignass A, Kucharzik T, Stallmach A, Sturm A, Schmidt C. [A surgically relevant summary of the addendum to the S3 guidelines of the DGVS on Crohn's disease and ulcerative colitis : Treatment of chronic inflammatory bowel diseases in the COVID-19 pandemic]. Chirurg 2021;92:30-3. [PMID: 33320280 DOI: 10.1007/s00104-020-01321-5] [Reference Citation Analysis]
65 Kjeldsen S, Nielsen J, Mertz Nørgård B, Kjeldsen J. Mesalazine in Inflammatory Bowel Disease and COVID-19: Hospitalization and Adverse In-Hospital Outcomes Based on Nationwide Data. Inflamm Bowel Dis 2021:izab299. [PMID: 34849917 DOI: 10.1093/ibd/izab299] [Reference Citation Analysis]
66 Dailey J, Kozhaya L, Dogan M, Hopkins D, Lapin B, Herbst K, Brimacombe M, Grandonico K, Karabacak F, Schreiber J, Liang BT, Salazar JC, Unutmaz D, Hyams JS. Antibody Responses to SARS-CoV-2 after Infection or Vaccination in Children and Young Adults with Inflammatory Bowel Disease. medRxiv 2021:2021. [PMID: 34159338 DOI: 10.1101/2021.06.12.21258810] [Reference Citation Analysis]
67 Mahil SK, Bechman K, Raharja A, Domingo-Vila C, Baudry D, Brown MA, Cope AP, Dasandi T, Graham C, Lechmere T, Malim MH, Meynell F, Pollock E, Seow J, Sychowska K, Barker JN, Norton S, Galloway JB, Doores KJ, Tree TIM, Smith CH. The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study. Lancet Rheumatol 2021;3:e627-37. [PMID: 34258590 DOI: 10.1016/S2665-9913(21)00212-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
68 Koletzko L, Klucker E, Le Thi TG, Breiteneicher S, Rubio-Acero R, Neuhaus L, Stark RG, Standl M, Wieser A, Török H, Koletzko S, Schwerd T. Following Pediatric and Adult IBD Patients through the COVID-19 Pandemic: Changes in Psychosocial Burden and Perception of Infection Risk and Harm over Time. J Clin Med 2021;10:4124. [PMID: 34575235 DOI: 10.3390/jcm10184124] [Reference Citation Analysis]
69 D'Silva KM, Wallace ZS. COVID-19 and Disease-Modifying Anti-rheumatic Drugs. Curr Rheumatol Rep 2021;23:28. [PMID: 33893890 DOI: 10.1007/s11926-021-00998-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
70 Izadi Z, Brenner EJ, Mahil SK, Dand N, Yiu ZZN, Yates M, Ungaro RC, Zhang X, Agrawal M, Colombel JF, Gianfrancesco MA, Hyrich KL, Strangfeld A, Carmona L, Mateus EF, Lawson-Tovey S, Klingberg E, Cuomo G, Caprioli M, Cruz-Machado AR, Mazeda Pereira AC, Hasseli R, Pfeil A, Lorenz HM, Hoyer BF, Trupin L, Rush S, Katz P, Schmajuk G, Jacobsohn L, Seet AM, Al Emadi S, Wise L, Gilbert EL, Duarte-García A, Valenzuela-Almada MO, Isnardi CA, Quintana R, Soriano ER, Hsu TY, D'Silva KM, Sparks JA, Patel NJ, Xavier RM, Marques CDL, Kakehasi AM, Flipo RM, Claudepierre P, Cantagrel A, Goupille P, Wallace ZS, Bhana S, Costello W, Grainger R, Hausmann JS, Liew JW, Sirotich E, Sufka P, Robinson PC, Machado PM, Griffiths CEM, Barker JN, Smith CH, Yazdany J, Kappelman MD; Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection (PsoProtect); the Secure Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD); and the COVID-19 Global Rheumatology Allianc., Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection (PsoProtect); the Secure Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD); and the COVID-19 Global Rheumatology Alliance (GRA). Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. JAMA Netw Open 2021;4:e2129639. [PMID: 34661663 DOI: 10.1001/jamanetworkopen.2021.29639] [Reference Citation Analysis]
71 Alvarado DM, Son J, Thackray LB, Diamond MS, Ding S, Ciorba MA; IBD Investigators Group at Washington University. Mesalamine Reduces Intestinal ACE2 Expression Without Modifying SARS-CoV-2 Infection or Disease Severity in Mice. bioRxiv 2021:2021. [PMID: 34373857 DOI: 10.1101/2021.07.23.453393] [Reference Citation Analysis]
72 Li XZ, Qiu Y, Jeffery L, Liu F, Feng R, He JS, Tan JY, Ye ZY, Lin SN, Ghosh S, Iacucci M, Chen MH, Mao R. Down-Regulation of Colonic ACE2 Expression in Patients With Inflammatory Bowel Disease Responding to Anti-TNF Therapy: Implications for COVID-19. Front Med (Lausanne) 2020;7:613475. [PMID: 33511147 DOI: 10.3389/fmed.2020.613475] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Viganò C, Mulinacci G, Palermo A, Barisani D, Pirola L, Fichera M, Invernizzi P, Massironi S. Impact of COVID-19 on inflammatory bowel disease practice and perspectives for the future. World J Gastroenterol 2021; 27(33): 5520-5535 [PMID: 34588749 DOI: 10.3748/wjg.v27.i33.5520] [Reference Citation Analysis]
74 Bezzio C, Armuzzi A, Furfaro F, Ardizzone S, Milla M, Carparelli S, Orlando A, Caprioli FA, Castiglione F, Viganò C, Ribaldone DG, Zingone F, Monterubbianesi R, Imperatore N, Festa S, Daperno M, Scucchi L, Ferronato A, Pastorelli L, Balestrieri P, Ricci C, Cappello M, Felice C, Fiorino G, Saibeni S; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study. Aliment Pharmacol Ther 2021;54:1432-41. [PMID: 34694009 DOI: 10.1111/apt.16663] [Reference Citation Analysis]
75 Teich N, Ludewig C, Schmelz R, Bästlein EC, Geißler S, Nagl S, Walldorf J, Krause T, Maaser C, Mohl W, Wedemeyer HH, Bauer T, Büning C, Grunert P, Hasselblatt P, Hänschen M, Kahl M, Engelke O, Schubert S, Holler B, Streetz K, Arnim UV, Schmidt K, Stallmach A; für die German IBD Study Group., Collaborators:., Jochen Maul, Berlin., Axel Schweitzer, Münster., Wolfgang Breit, Dinkelsbühl., Jan-Hinnerk Hofer, Köln., Marc Eisold, Mössingen., Michael R. Mroß, Berlin., Stefanie Howaldt, Hamburg., Stefanie Strobl, Ingolstadt., Robert Ehehalt, Heidelberg., Klaus Schmidt, Lübeck., Carsten Triller, Heinsberg., Serhat Aymaz, Düren., Thorsten Brechmann, Bochum., Axel Dignaß, Frankfurt., Elisabeth Schnoy, Augsburg., Bernd Swarovsky, Albstadt., Dr. med. Birgit Gerhard, Berlin., Doris Zink, Nürnberg., Ulrich Finger, Berlin., Franz Josef Heil, Andernach., Gerd-Rüdiger Franke, Dinkelsbühl., Günther Böhm, Ludwigshafen., Jens Hunkemöller, Oberberg., Martin Schmidt-Lauber, Oldenburg., Mirko Vonderach, Oldenburg., Olaf Mensler, Oberberg., Rainer Kunz, Fürstenfeldbruck., Richard Kölble, Düsseldorf., Christoph Rother, Sundern., Ulf Klönne, Göttingen., Ulrich Graefe, Berlin., Wolfgang Schwarz, Hamburg., Georg Schmitz, Düren., Hans Vibrans, Chemnitz., Thomas Witthöft, Stade., Tobias Klugmann, Leipzig., Martin Reuther, Lilienthal., Frank Bülow, Kassel., Carsten Ising, Waldbröl., Christoph Balzer, Schwandorf., Julia Morgenstern, Köln., Markus Casper, Saarbrücken., Ron Winograd, Aachen., Tilman Pickartz, Greifswald., Marco Wagner, Wipperfürth., Christoph Schmidt, Bonn., Wolfgang Vogt, Esslingen., Sabine Blau, Frankfurt/Main., Rolf Seipel, Kronach., Gisela Felten, Herne., Philipp A. Reuken, Jena., Jörg Kapp, Uelzen., Maximilian Gemeinhardt, Garmisch-Partenkirchen., Jörg Christian Metzler, Schwäbisch Gmünd., Martin Hoffstadt, Iserlohn., Susanne Wüchner-Hofmann, Darmstadt. [Effects of SARS-CoV-2 Infection on Symptoms and Therapy of Inflammatory Bowel Disease]. Z Gastroenterol 2021;59:1189-96. [PMID: 34748206 DOI: 10.1055/a-1508-6734] [Reference Citation Analysis]
76 Rieker L, Hofer J, Petzold G, Ellenrieder V, Amanzada A. Induction of remission with tacrolimus in a patient with severe acute, cortisone refractory ulcerative colitis and severe Covid-19 pneumonia: a case report. BMC Gastroenterol 2022;22:22. [PMID: 35033015 DOI: 10.1186/s12876-022-02094-3] [Reference Citation Analysis]
77 Jena A, Mishra S, Deepak P, Kumar-M P, Sharma A, Patel YI, Kennedy NA, Kim AHJ, Sharma V, Sebastian S. Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis. Autoimmun Rev 2021;:102927. [PMID: 34474172 DOI: 10.1016/j.autrev.2021.102927] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
78 van Eijk LE, Binkhorst M, Bourgonje AR, Offringa AK, Mulder DJ, Bos EM, Kolundzic N, Abdulle AE, van der Voort PH, Olde Rikkert MG, van der Hoeven JG, den Dunnen WF, Hillebrands JL, van Goor H. COVID-19: immunopathology, pathophysiological mechanisms, and treatment options. J Pathol 2021;254:307-31. [PMID: 33586189 DOI: 10.1002/path.5642] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
79 Rao A, Puertolas M, Runde J. COVID-19 and Gastrointestinal and Hepatobiliary Diseases. Pediatr Ann 2021;50:e315-9. [PMID: 34398713 DOI: 10.3928/19382359-20210721-02] [Reference Citation Analysis]
80 Miyoshi J, Matsuura M, Hisamatsu T. Safety evaluation of ustekinumab for moderate-to-severe ulcerative colitis. Expert Opin Drug Saf 2021. [PMID: 34511011 DOI: 10.1080/14740338.2021.1980536] [Reference Citation Analysis]
81 Di Ruscio M, Lunardi G, Buonfrate D, Gobbi F, Bertoli G, Piccoli D, Conti A, Geccherle A, Variola A. A Seroprevalence Study of Anti-SARS-CoV-2 Antibodies in Patients with Inflammatory Bowel Disease during the Second Wave of the COVID-19 Pandemic in Italy. Medicina (Kaunas) 2021;57:1048. [PMID: 34684085 DOI: 10.3390/medicina57101048] [Reference Citation Analysis]
82 Xiang Y, Wong KC, So HC. Exploring Drugs and Vaccines Associated with Altered Risks and Severity of COVID-19: A UK Biobank Cohort Study of All ATC Level-4 Drug Categories Reveals Repositioning Opportunities. Pharmaceutics 2021;13:1514. [PMID: 34575590 DOI: 10.3390/pharmaceutics13091514] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Wellens J, Edmans M, Obolski U, McGregor CG, Simmonds P, Turner M, Jarvis L, Skelly D, Dunachie S, Barnes E, Eyre DW, Colombel JF, Wong SY, Klenerman P, Lindsay JO, Satsangi J, Thompson CP. Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease. Gut 2021:gutjnl-2021-326312. [PMID: 34911744 DOI: 10.1136/gutjnl-2021-326312] [Reference Citation Analysis]
84 Papa A, Scaldaferri F, Vetrone LM, Neri M, Gasbarrini A, Lopetuso LR. How to Face the Advent of SARS-CoV-2 Vaccination in IBD Patients: Another Task for Gastroenterologists. Vaccines (Basel) 2021;9:248. [PMID: 33808983 DOI: 10.3390/vaccines9030248] [Reference Citation Analysis]
85 Marjot T, Buescher G, Sebode M, Barnes E, Barritt AS 4th, Armstrong MJ, Baldelli L, Kennedy J, Mercer C, Ozga AK, Casar C, Schramm C;  contributing Members and Collaborators of ERN RARE-LIVER/COVID-Hep/SECURE-Cirrhosis; Moon AM, Webb GJ, Lohse AW. SARS-CoV-2 infection in patients with autoimmune hepatitis. J Hepatol. 2021;74:1335-1343. [PMID: 33508378 DOI: 10.1016/j.jhep.2021.01.021] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 17.0] [Reference Citation Analysis]
86 Oikonomou KG, Papamichalis P, Zafeiridis T, Xanthoudaki M, Papapostolou E, Valsamaki A, Bouliaris K, Papamichalis M, Karvouniaris M, Vlachostergios PJ, Skoura AL, Komnos A. Gastroenterology and liver disease during COVID-19 and in anticipation of post-COVID-19 era: Current practice and future directions. World J Clin Cases 2021; 9(19): 4918-4938 [PMID: 34307544 DOI: 10.12998/wjcc.v9.i19.4918] [Reference Citation Analysis]
87 Dailey J, Kozhaya L, Dogan M, Hopkins D, Lapin B, Herbst K, Brimacombe M, Grandonico K, Karabacak F, Schreiber J, Liang BT, Salazar JC, Unutmaz D, Hyams JS. Antibody Responses to SARS-CoV-2 After Infection or Vaccination in Children and Young Adults With Inflammatory Bowel Disease. Inflamm Bowel Dis 2021:izab207. [PMID: 34528661 DOI: 10.1093/ibd/izab207] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Magro F, Nuzzo A, Abreu C, Libânio D, Rodriguez-Lago I, Pawlak K, Hollenbach M, Brouwer WP, Siau K. COVID-19 in gastroenterology: Where are we now? Current evidence on the impact of COVID-19 in gastroenterology. United European Gastroenterol J 2021. [PMID: 34190413 DOI: 10.1002/ueg2.12115] [Reference Citation Analysis]
89 Concas G, Barone M, Francavilla R, Cristofori F, Dargenio VN, Giorgio R, Dargenio C, Fanos V, Marcialis MA. Twelve Months with COVID-19: What Gastroenterologists Need to Know. Dig Dis Sci 2021. [PMID: 34333726 DOI: 10.1007/s10620-021-07158-0] [Reference Citation Analysis]
90 Kaplan GG, Windsor JW, Crain J, Barrett L, Bernstein CN, Bitton A, Chauhan U, Coward S, Fowler S, Ghia JE, Gibson DL, Griffiths AM, Jones JL, Khanna R, Kuenzig ME, Lakatos PL, Lee K, Mack DR, Marshall JK, Mawani M, Murthy SK, Panaccione R, Seow CH, Targownik LE, Zelinsky S, Benchimol EI. Crohn's and Colitis Canada's 2021 Impact of COVID-19 & Inflammatory Bowel Disease in Canada: A Knowledge Translation Strategy. J Can Assoc Gastroenterol 2021;4:S10-9. [PMID: 34755034 DOI: 10.1093/jcag/gwab028] [Reference Citation Analysis]
91 Mahil SK, Bechman K, Raharja A, Domingo-Vila C, Baudry D, Brown MA, Cope AP, Dasandi T, Graham C, Khan H, Lechmere T, Malim MH, Meynell F, Pollock E, Sychowska K, Barker JN, Norton S, Galloway JB, Doores KJ, Tree T, Smith CH. Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study. Lancet Rheumatol 2021. [PMID: 34778846 DOI: 10.1016/S2665-9913(21)00333-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
92 Din S, Gaya D, Kammermeier J, Lamb CA, Macdonald J, Moran G, Parkes G, Pollok R, Sebastian S, Segal J, Selinger C, Smith PJ, Steed H, Arnott ID. Inflammatory bowel disease clinical service recovery during the COVID-19 pandemic. Frontline Gastroenterol 2022;13:77-81. [PMID: 34966535 DOI: 10.1136/flgastro-2021-101805] [Reference Citation Analysis]
93 Dalal RS, McClure E, Marcus J, Winter RW, Hamilton MJ, Allegretti JR. COVID-19 Vaccination Intent and Perceptions Among Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2021;19:1730-1732.e2. [PMID: 33549869 DOI: 10.1016/j.cgh.2021.02.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 15.0] [Reference Citation Analysis]
94 Mao R, Rieder F, Ben-Horin S, Kaplan GG, Ng SC, Wong GL, Ghosh S, Chen MH. Implications of COVID-19 for patients with pre-existing digestive diseases: an update. Lancet Gastroenterol Hepatol. 2021;6:258-260. [PMID: 33539813 DOI: 10.1016/s2468-1253(21)00025-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
95 Siegel CA, Melmed GY, McGovern DPB, Rai V, Krammer F, Rubin DT, Abreu MT, Dubinsky MC. SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting. Gut. 2021;70:635-640. [PMID: 33472895 DOI: 10.1136/gutjnl-2020-324000] [Cited by in Crossref: 35] [Cited by in F6Publishing: 41] [Article Influence: 35.0] [Reference Citation Analysis]
96 Alrashed F, Battat R, Abdullah I, Charabaty A, Shehab M. Impact of medical therapies for inflammatory bowel disease on the severity of COVID-19: a systematic review and meta-analysis. BMJ Open Gastroenterol 2021;8:e000774. [PMID: 34725056 DOI: 10.1136/bmjgast-2021-000774] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
97 Meyer A, Semenzato L, Zureik M, Weill A, Carbonnel F, Dray-Spira R. Risk of severe COVID-19 in patients treated with IBD medications: a French nationwide study. Aliment Pharmacol Ther 2021;54:160-6. [PMID: 34110040 DOI: 10.1111/apt.16410] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
98 Khan N, Mahmud N, Trivedi C, Reinisch W, Lewis JD. Risk factors for SARS-CoV-2 infection and course of COVID-19 disease in patients with IBD in the Veterans Affair Healthcare System. Gut 2021;70:1657-64. [PMID: 33753416 DOI: 10.1136/gutjnl-2021-324356] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
99 Hadi Y, Dulai PS, Kupec J, Mohy-Ud-Din N, Jairath V, Farraye FA, Kochhar GS. Incidence, outcomes, and impact of COVID-19 on inflammatory bowel disease: Propensity matched research network analysis. Aliment Pharmacol Ther 2021. [PMID: 34904240 DOI: 10.1111/apt.16730] [Reference Citation Analysis]
100 Kucharzik T, Ellul P, Greuter T, Rahier JF, Verstockt B, Abreu C, Albuquerque A, Allocca M, Esteve M, Farraye FA, Gordon H, Karmiris K, Kopylov U, Kirchgesner J, MacMahon E, Magro F, Maaser C, de Ridder L, Taxonera C, Toruner M, Tremblay L, Scharl M, Viget N, Zabana Y, Vavricka S. ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. J Crohns Colitis 2021;15:879-913. [PMID: 33730753 DOI: 10.1093/ecco-jcc/jjab052] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
101 Sperger J, Shah KS, Lu M, Zhang X, Ungaro RC, Brenner EJ, Agrawal M, Colombel JF, Kappelman MD, Kosorok MR. Development and validation of multivariable prediction models for adverse COVID-19 outcomes in patients with IBD. BMJ Open 2021;11:e049740. [PMID: 34772750 DOI: 10.1136/bmjopen-2021-049740] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
102 Johnson SD, Olwenyi OA, Bhyravbhatla N, Thurman M, Pandey K, Klug EA, Johnston M, Dyavar SR, Acharya A, Podany AT, Fletcher CV, Mohan M, Singh K, Byrareddy SN. Therapeutic implications of SARS-CoV-2 dysregulation of the gut-brain-lung axis. World J Gastroenterol 2021; 27(29): 4763-4783 [PMID: 34447225 DOI: 10.3748/wjg.v27.i29.4763] [Reference Citation Analysis]
103 Attauabi M, Seidelin J, Burisch J; Danish COVID-IBD Study Group. Association between 5-aminosalicylates in patients with IBD and risk of severe COVID-19: an artefactual result of research methodology? Gut 2021:gutjnl-2021-324397. [PMID: 33658323 DOI: 10.1136/gutjnl-2021-324397] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]